Free Trial

Harrow Q4 2022 Earnings Report

Harrow logo
$30.72 -0.97 (-3.06%)
As of 01/31/2025 04:00 PM Eastern

Harrow EPS Results

Actual EPS
$0.07
Consensus EPS
-$0.15
Beat/Miss
Beat by +$0.22
One Year Ago EPS
N/A

Harrow Revenue Results

Actual Revenue
$20.33 million
Expected Revenue
$23.26 million
Beat/Miss
Missed by -$2.93 million
YoY Revenue Growth
N/A

Harrow Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Conference Call Audio

Harrow Earnings Headlines

Harrow price target lowered to $58 from $65 at Craig-Hallum
He called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.
With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only set to be released from its constraints … it could be about to explode. Trump has vowed to roll back Biden’s “crusade against crypto” on his first day in office.
Harrow, Inc. (NASDAQ:HROW) Sees Board Member Resignation
Harrow announces Amir Shojaei, PharmD, PhD joins as CSO
See More Harrow Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Harrow? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Harrow and other key companies, straight to your email.

About Harrow

Harrow (NASDAQ:HROW) operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

View Harrow Profile

More Earnings Resources from MarketBeat